This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de Bionomics

Salud financiera controles de criterios 6/6

Bionomics has a total shareholder equity of A$47.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$56.3M and A$8.6M respectively.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$30.70m
Patrimonio	AU$47.72m
Total pasivo	AU$8.59m
Activos totales	AU$56.31m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: B1N's short term assets (A$33.1M) exceed its short term liabilities (A$3.7M).

Pasivo a largo plazo: B1N's short term assets (A$33.1M) exceed its long term liabilities (A$4.9M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: B1N is debt free.

Reducción de la deuda: B1N has no debt compared to 5 years ago when its debt to equity ratio was 63.9%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: B1N has sufficient cash runway for more than a year based on its current free cash flow.

Pronóstico de cash runway: B1N has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 9% each year.

This company listing is no longer active

Salud financiera de hoja de balance de Bionomics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Revenue beats expectations

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

New 90-day high: €0.27

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - €0.0082 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera